Miraqules co-founder and CEO Sabir Hossain always knew he wanted to follow in his father’s footsteps and run his own business. But he never thought he’d launch a biotech company built around a technology that would have been able to help his father after a near-tragic accident years earlier left him almost bleeding to death.
Bengaluru-based Miraqules developed a nanotechnology in powder form that mimics blood clotting proteins. The blood clotting powder rapidly produces fibrous compounds at room temperature that are a high volume to ratio and can absorb blood quickly when applied.
“This is a product that will give you feedback instantly,” Hossain told TechCrunch. “If there is a person bleeding, you apply it, and the bleeding stops. This whole thing happens within one or two minutes.”
Miraqules is a Top 20 Startup Battlefield finalist and will be presenting this technology on stage at TechCrunch Disrupt 2025, this week in San Francisco.
Hossain said he developed the technology almost by accident.
He went to grad school for biomedical engineering and started working in a research lab focused on biomaterials where his job was essentially to mimic the work of a doctorate student.
“I was really bad at that, actually,” Hossain said. “Her job was to create 3D structures that will help in bone tissue growth, that could help in bone generation. Every time I was synthesizing that material, it was getting dismantled.”
One day he took the dismantled particles and ground it into a powder. He brought this powder to a group working on blood clotting that was struggling to mix their solution properly to see if it could help — and it worked.
“It clotted the whole blood within maybe five to 10 seconds. I rushed to my professor and then from there we started to think about what made it happen,” Hossain said. “We came up with the completely new process of combining off-the-shelf materials into a nanomaterial that mimics blood clotting proteins.”
Hossain then paired up with his childhood friend, Mubeen Midda, and they started trying to develop the technology so it could be taken out of the lab — with as little funding as possible.
Since then, the company has been able to secure 11 patents across seven different countries, including India, the United States, and Israel.
Miraqules’ tech is already being piloted in a trauma care center in India, and the company expects to get its regulatory clearance in India within the next few months. It also is on track to receive clearance from the U.S. Food and Drug Administration in 2026.
“One thing we did from the beginning, we directly went to the U.S. FDA, there is something called pre-submission. We tried to get their feedback on what other necessary things that we need to do to get this product approved, that helped us a lot.”
The company has reached these milestones with less than $700,000 in capital raised, largely from grants.
Miraqules is looking to ramp up deployment and pilot programs heading into next year. It has already received potential interest from 10 different hospital chains in India and the Israeli Defense Forces.
If you want to learn from Miraqules firsthand, and see dozens of additional pitches, attend valuable workshops, and make the connections that drive business results, head here to learn more about this year’s Disrupt, held October 27 to 29 in San Francisco.
